Early results from a clinical trial of AADC gene therapy for Parkinson's disease

被引：0
|
作者：
Eberling, JL
Bankiewicz, KS
McGuire, D
Aminoff, M
Christine, C
Starr, P
Larson, P
Jagust, WJ
机构：
来源：
NEUROLOGY | 2006年 / 66卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：276 / 277
页数：2
相关论文
共 50 条
  • [1] AADC Gene Therapy for Advanced Parkinson's Disease: Interim Results of a Phase 1b Trial
    Ravina, Bernard
    Christine, Chadwick W.
    Larson, Paul S.
    Van Laar, Amber
    Richardson, R. Mark
    Kells, Adrian
    Boot, Brendon
    Martin, Alastair
    Thompson, Marin
    Bankiewicz, Krystof S.
    [J]. MOLECULAR THERAPY, 2018, 26 (05) : 32 - 32
  • [2] Gene therapy for Parkinson disease: implications from a clinical study of AADC deficiency
    Muramatsu, S.
    [J]. HUMAN GENE THERAPY, 2018, 29 (12) : A19 - A20
  • [3] Intraputaminal AADC gene therapy for Parkinson's disease: Results of a phase 1 study
    Aminoff, M. J.
    Christine, C. W.
    Starr, P. A.
    Larson, P. S.
    Eberling, J. L.
    Jagust, W. J.
    Hawkins, R. A.
    VanBrocklin, H. F.
    Bankiewicz, K. S.
    [J]. MOVEMENT DISORDERS, 2009, 24 : S254 - S255
  • [4] Intraputaminal AADC gene therapy for advanced Parkinson's disease: Interim Results of a Phase 1b Trial
    Christine, Chadwick
    Bankiewicz, Krzysztoffs
    Van Laar, Amber
    Richardson, Mark
    Ravina, Bernard
    Kells, Adreian
    Boot, Brendon
    Martin, Alastair
    Thompson, Marin
    Larson, Paul
    [J]. NEUROLOGY, 2017, 89 (08) : E99 - E99
  • [5] Intraputaminal AADC gene therapy for advanced Parkinson's disease: interim results of a phase 1b Trial
    Ravina, B.
    Christine, C.
    Bankiewicz, K.
    Van Laar, A.
    Richardson, M.
    Kells, A.
    Boot, B.
    Martin, A.
    Thompson, M.
    Larson, P.
    [J]. HUMAN GENE THERAPY, 2017, 28 (12) : A6 - A6
  • [6] Gene therapy in the putamen for curing AADC deficiency and Parkinson's disease
    Hwu, Paul Wuh-Liang
    Kiening, Karl
    Anselm, Irina
    Compton, David R.
    Nakajima, Takeshi
    Opladen, Thomas
    Pearl, Phillip L.
    Roubertie, Agathe
    Roujeau, Thomas
    Muramatsu, Shin-ichi
    [J]. EMBO MOLECULAR MEDICINE, 2021, 13 (09)
  • [7] Three-year safety and clinical outcomes from the PD-1101 trial of AADC gene therapy for advanced Parkinson's disease
    Christine, C.
    Richardson, R.
    Van Laar, A.
    Thompson, M.
    Herbert, K.
    Li, C.
    Liang, G.
    Fine, E.
    Larson, P.
    [J]. MOVEMENT DISORDERS, 2020, 35 : S391 - S392
  • [8] AADC gene therapy administered via a posterior approach: 18-month results from the PD-1102 trial in advanced Parkinson's disease
    Factor, S.
    Van Laar, A.
    Richardson, R.
    Christine, C.
    Larson, P.
    Kostyk, S.
    Lonser, R.
    Li, C.
    Liang, G.
    Meier, A.
    Fine, E.
    Gross, R.
    [J]. MOVEMENT DISORDERS, 2020, 35 : S395 - S395
  • [9] Depletion of AADC activity in caudate nucleus and putamen of Parkinson's disease patients; implications for ongoing AAV2-AADC gene therapy trial
    Ciesielska, Agnieszka
    Samaranch, Lluis
    San Sebastian, Waldy
    Dickson, Dennis W.
    Goldman, Samuel
    Forsayeth, John
    Bankiewicz, Krystof S.
    [J]. PLOS ONE, 2017, 12 (02):
  • [10] Safety and tolerability of putaminal AADC gene therapy for Parkinson disease
    Christine, C. W.
    Starr, P. A.
    Larson, P. S.
    Eberling, J. L.
    Jagust, W. J.
    Hawkins, R. A.
    VanBrocklin, H. F.
    Wright, J. F.
    Bankiewicz, K. S.
    Aminoff, M. J.
    [J]. NEUROLOGY, 2009, 73 (20) : 1662 - 1669
12345